Haleon and Aptar Pharma launch Otrivin Nasal Mist, a new generation nasal spray with microdroplet technology for greater comfort and ease of use for treating nasal congestion; the product will first be available in Poland, Greece and Portugal

Sample article from our Health Care Sector

October 23, 2023 (press release) –

Otrivin Nasal Mist, a new generation of nasal spray, has been launched to bring greater comfort and ease of use to people suffering from nasal congestion due to colds, allergic rhinitis and sinusitis[3]. The new innovation, developed by consumer health company Haleon and Aptar Pharma, uses new microdroplet technology[1] to dispense a full but gentle mist which evenly covers inflamed areas, with no dripping at the back of the nose and throat[2].

The new design is a significant improvement on other pump devices[2][5]. A shorter nozzle means more comfort when using the product, while the one push button ensures ease of application, particularly for people who may have limited movement and strength in their hands[6]. The Otrivin Nasal Mist begins working in as little as 2 minutes after application and lasts for up to 12 hours.[3]

Nasal congestion is one of the main symptoms of colds and flu and affects two-thirds of the world’s population every year[4]. Caused by inflammation of the surfaces in the nose, nasal congestion can also be caused by rhinosinusitis, upper respiratory tract infections and allergic rhinitis.[3]

Fernando Bódalo, Vice-President, Global Brand Lead Respiratory at Haleon, said: “Nasal congestion related to colds, flu and allergic rhinitis is commonplace. Medicated nasal sprays are the most effective way to relieve nasal congestion when used correctly.[3] Yet we know that only half of people use a nasal spray, largely due to discomfort caused by the1 physical sensation and action of current sprays.[4] The good news is that there is a new generation of nasal spray available, using specialist technology that greatly improves comfort in use[5][6].”

Otrivin Nasal Mist is the result of a seven-year collaboration between researchers at Haleon and Aptar Pharma, developing Aptar’s proprietary pump technology (Lateral Control System) and ensuring compatibility with Haleon’s Otrivin formulations. This is the first worldwide launch of a product using the Lateral Control System technology.

Stefan Ritsche, President, Global Market Development, Consumer Health Care Division, Aptar Pharma, said: “Aptar Pharma is proud of our partnership with Haleon in developing this innovative nasal spray technology. Our patented Lateral Control System technology offers consumers an improved delivery experience and will be a real game changer in the decongestant and nasal spray markets.”

How to use NEW Otrivin Nasal Mist[1]:

  • Open the cap by pressing and turning the nozzle
  • Push the blue button five times to prime the device
  • Place nozzle into nostril almost vertically and press button once to mist

Otrivin Nasal Mist is available from today in pharmacies across Poland, Greece and Portugal, before being rolled out to other parts of the world.


* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.